RBC Capital Rates NewAmsterdam Pharma (NAMS) buy

RBC Capital maintains its buy rating for NewAmsterdam Pharma with a $51 price target, a 50.49% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 12:01 PM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital rated NewAmsterdam Pharma Company N.V. ($NAMS) "buy" with a $51 price target on June 30, 2026.

Since the rating, $NAMS is up 9.2% after 1 week, down 16.0% after 1 month and down 41.5% to date (from the $33.89 close on Jun 30, 2026).

NAMS NewAmsterdam Pharma Company N.V.

$19.83 -43.66% year to date

Daily close · Oct 16, 2026

Key Points

RBC Capital reiterated its buy rating on NewAmsterdam Pharma with a $51 price target on June 30, 2026.
RBC Capital's $51 price target implies 50.49% upside from NewAmsterdam Pharma Company N.V.'s ($NAMS) current $33.89 share price.
Shares of NAMS on NasdaqGM traded near $33.87 on Tuesday, with a market cap of about $3.89 billion.
Institutional investors like FMR LLC increased their holdings by 36.7%, ending with 8.77 million shares.

Get $NAMS trade alerts by text

We text you when insiders, Congress or big funds trade $NAMS. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated NewAmsterdam Pharma Company N.V. alert may contain errors. Disclosures

RBC Capital analyst Leonid Timashev reiterated a buy rating on NewAmsterdam Pharma Company N.V. (NasdaqGM: NAMS) on June 30, 2026. The firm set a price target of $51 for the biotechnology company, which focuses on therapies for cardiometabolic diseases.

Analyst rating track record

RBC Capital vs. the S&P 500

YTD return +8.89% hypothetical

All-time return +12.74% S&P 500 +30.78%

vs. S&P 500 -18.04% behind the index

Hypothetical returns from RBC Capital's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in NewAmsterdam Pharma

Frazier Life Sciences Management held its position steady with 16.94 million shares valued at about $542.4 million. Capital World Investors increased its stake by 1.13 million shares, bringing its total to 11.11 million shares worth approximately $355.6 million, marking an 11.3% increase. RA Capital Management maintained its holdings with 9.55 million shares valued at $305.7 million. FMR LLC significantly boosted its position by 2.35 million shares, a 36.7% increase, resulting in 8.77 million shares valued at $280.6 million.

NewAmsterdam Pharma Company N.V. Stock Up 50.7%

Shares of NewAmsterdam Pharma traded near $33.87 on Tuesday. The company has a market cap of approximately $3.89 billion and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is a low 0.078, indicating minimal volatility. It has a 52-week range between $17.97 and $42.21, with a 50-day moving average of $32.66 and a 200-day moving average of $33.43.

12-month forecast

$NAMS price target

NewAmsterdam Pharma Company N.V. daily closes and this analyst's $51 target. Not advice.

Insider Buying and Selling at NewAmsterdam Pharma Company N.V.

Chief Accounting Officer Louise Frederika Kooij was active in recent transactions, selling 40,000 shares at an average price of $30.20 on June 22, 2026, as part of a planned transaction. She also purchased 40,000 shares at $11.28 on the same day. Earlier, on May 26, 2026, Kooij sold 65,000 shares at $35.69 in a planned sale, while also buying 65,000 shares at $10.07.

Analysts Set New Price Targets

On June 30, 2026, RBC Capital maintained its buy rating and set a $51 price target. Guggenheim and Needham also maintained buy ratings earlier in the year, with price targets of $45 and $48, respectively. Overall, the consensus among 14 analysts is a buy, with a mean price target of $49.18.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company headquartered in Naarden, Netherlands. It focuses on developing therapies for cardiometabolic diseases, including Obicetrapib, an oral CETP inhibitor for lowering LDL-C. The company is led by CEO Dr. Michael Harvey Davidson and employs around 100 people.

Bottom Line

RBC Capital's reiterated buy rating and $51 price target underline continued confidence in NewAmsterdam Pharma's potential. While the company's current lack of profitability affects its forward P/E ratio, its focus on innovative therapies keeps it on the radar of investors and analysts alike. Institutional interest remains strong, with significant increases in holdings by funds like FMR LLC.